| Trial Name | Description |
| CO.32 GI |
Dr. Terry Zwiep Not Open Yet - The NEO-RT Trial: A PHASE 3 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION VERSUS CHEMORADIOTHERAPY FOR EARLY RECTAL CANCER |
| CLARITY-Gastric GI |
Dr. Daniel Breadner A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenoca |
| CRC.10 GI_CIRCULATE-North America |
Dr. E Tsvetkova Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-North America) |
| GA.4 GI |
Dr. D. Breadner A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma |
| ARTEMIDE-Biliary01 |
Dr. D. Breadner Not open yet - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer with Curative Intent |
| HERIZON BTC-302 |
Dr. E. Tsvetkova An open-label randomized trial of the efficacy and safety of zanidatamab with standard of care therapy against standard of care therapy alone for advanced HER2-positive biliary tract cancer |
| FORTITUDE 102 Gastric-GEJ |
Dr. M. Vincent A Phase 1B/3 Study of Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone in Subjects with Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2B Overexpression |
| CHASe-PDAC GI |
Dr. J. Lenehan An open-label, single-arm, phase 1 study of the combination of FMT and gemcitabine with nab-paclitaxel as first-line therapy in patients with advanced pancreatic ductal adenocarcinoma. |